Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses - PubMed (original) (raw)
Clinical Trial
. 2000 Nov;54(11):849-55.
doi: 10.1038/sj.ejcn.1601093.
Affiliations
- PMID: 11114680
- DOI: 10.1038/sj.ejcn.1601093
Clinical Trial
Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses
B L Chiang et al. Eur J Clin Nutr. 2000 Nov.
Abstract
Objective: To define the cellular basis for immune enhancement by a probiotic lactic acid bacteria strain (Bifidobacterium lactis HN019); and to determine whether immune enhancement can be optimized by delivery in oligosaccharide-enriched low-fat milk.
Design: A double-blind, three-stage before-and-after intervention trial.
Setting: Taipei Medical College Hospital, Taipei, Taiwan.
Subjects: Fifty healthy Taiwanese citizens (age range 41-81; median 60) randomly allocated to two groups.
Interventions: In stage 1 (run-in control stage) all subjects consumed reconstituted low-fat milk (LFM) for 3 weeks; in stage 2 (probiotic intervention) subjects consumed B. lactis in LFM (group A) or B. lactis in lactose-hydrolysed LFM (group B) for 3 weeks; in stage 3 all subjects returned to non-supplemented LFM for a further 3 weeks (washout stage). The innate immune functions of two different leucocyte types (polymorphonuclear (PMN) cells and natural killer (NK) cells) were assessed at four time points via in vitro analyses on peripheral blood samples.
Results: While consumption of LFM alone had no significant effect on immune responses, stage 2 results indicated significantly enhanced PMN cell phagocytosis and NK cell tumour killing activity following consumption of milk containing B. lactis. These increases levelled off following cessation of B. lactis consumption, but remained above the pre-treatment values. Increases in PMN and NK cell activity were greatest among subjects who consumed B. lactis in lactose-hydrolysed LFM.
Conclusions: Dietary consumption of the probiotic bacterium B. lactis HN019 enhanced immune function of two different types of leucocytes; the degree of enhancement was increased by consuming B. lactis in an oligosaccharide-rich substrate.
Sponsorship: Financial support was provided by the New Zealand Dairy Board.
Similar articles
- Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001.
Sheih YH, Chiang BL, Wang LH, Liao CK, Gill HS. Sheih YH, et al. J Am Coll Nutr. 2001 Apr;20(2 Suppl):149-56. doi: 10.1080/07315724.2001.10719027. J Am Coll Nutr. 2001. PMID: 11349938 Clinical Trial. - Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019.
Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Gill HS, et al. Am J Clin Nutr. 2001 Dec;74(6):833-9. doi: 10.1093/ajcn/74.6.833. Am J Clin Nutr. 2001. PMID: 11722966 Clinical Trial. - Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019).
Arunachalam K, Gill HS, Chandra RK. Arunachalam K, et al. Eur J Clin Nutr. 2000 Mar;54(3):263-7. doi: 10.1038/sj.ejcn.1600938. Eur J Clin Nutr. 2000. PMID: 10713750 Clinical Trial. - The Effect of Bifidobacterium animalis ssp. lactis HN019 on Cellular Immune Function in Healthy Elderly Subjects: Systematic Review and Meta-Analysis.
Miller LE, Lehtoranta L, Lehtinen MJ. Miller LE, et al. Nutrients. 2017 Feb 24;9(3):191. doi: 10.3390/nu9030191. Nutrients. 2017. PMID: 28245559 Free PMC article. Review. - Summary of probiotic activities of Bifidobacterium lactis HN019.
Sanders ME. Sanders ME. J Clin Gastroenterol. 2006 Oct;40(9):776-83. doi: 10.1097/01.mcg.0000225576.73385.f0. J Clin Gastroenterol. 2006. PMID: 17016131 Review.
Cited by
- Bifidobacterium animalis subsp. lactis HN019 live probiotics and postbiotics: production strategies and bioactivity evaluation for potential therapeutic properties.
D'ambrosio S, Dabous A, Sadiq S, Casillo A, Schiraldi C, Cassese E, Bedini E, Corsaro MM, Cimini D. D'ambrosio S, et al. Front Bioeng Biotechnol. 2024 Jul 9;12:1379574. doi: 10.3389/fbioe.2024.1379574. eCollection 2024. Front Bioeng Biotechnol. 2024. PMID: 39055336 Free PMC article. - Influence of Lactobacillus rhamnosus Supplementation on the Glycaemic Index, Lipid Profile, and Microbiome of Healthy Elderly Subjects: A Preliminary Randomized Clinical Trial.
Chaiyasut C, Sivamaruthi BS, Thangaleela S, Sisubalan N, Bharathi M, Khongtan S, Kesika P, Sirilun S, Choeisoongnern T, Peerajan S, Fukngoen P, Sittiprapaporn P, Rungseevijitprapa W. Chaiyasut C, et al. Foods. 2024 Apr 23;13(9):1293. doi: 10.3390/foods13091293. Foods. 2024. PMID: 38731665 Free PMC article. - Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV.
Ray S, Narayanan A, Vesterbacka J, Blennow O, Chen P, Gao Y, Gabarrini G, Ljunggren HG, Buggert M, Manoharan L, Chen MS, Aleman S, Sönnerborg A, Nowak P. Ray S, et al. NPJ Biofilms Microbiomes. 2023 Dec 20;9(1):104. doi: 10.1038/s41522-023-00461-w. NPJ Biofilms Microbiomes. 2023. PMID: 38123600 Free PMC article. - Modulatory Effect of Beneficial Enterococci and Their Enterocins on the Blood Phagocytes in Murine Experimental Trichinellosis.
Vargová M, Revajová V, Lauková A, Hurníková Z, Dvorožňáková E. Vargová M, et al. Life (Basel). 2023 Sep 18;13(9):1930. doi: 10.3390/life13091930. Life (Basel). 2023. PMID: 37763333 Free PMC article. - The Effect of Delivery Matrix on Bifidobacterium animalis subsp. lactis HN019 Survival through In Vitro Human Digestion.
Yeung N, Forssten SD, Saarinen MT, Anjum M, Ouwehand AC. Yeung N, et al. Nutrients. 2023 Aug 11;15(16):3541. doi: 10.3390/nu15163541. Nutrients. 2023. PMID: 37630731 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources